541 related articles for article (PubMed ID: 25996827)
21. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
[No Abstract] [Full Text] [Related]
22. Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection.
Clay TD; Bowyer SE
Anticancer Drugs; 2018 Sep; 29(8):802-805. PubMed ID: 29846245
[TBL] [Abstract][Full Text] [Related]
23. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
24. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
25. Gut dysbiosis: not only with checkpoint inhibitors!
Piroth M; Frenard C; Quereux G; Khammari A; Corvec S; Dréno B
Clin Exp Dermatol; 2020 Mar; 45(2):247-249. PubMed ID: 31222907
[No Abstract] [Full Text] [Related]
26. Acute intraventricular conduction disorder due to combination therapy with dabrafenib and trametinib for metastatic melanoma: Case report.
Yamamura K; Matsushita S; Aoki M; Kusumoto K
J Dermatol; 2018 May; 45(5):e120-e121. PubMed ID: 29178523
[No Abstract] [Full Text] [Related]
27. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
[No Abstract] [Full Text] [Related]
28. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
[TBL] [Abstract][Full Text] [Related]
29. Acanthoma planoepitheliale hyperkeratoticum, lesions associated with BRAF inhibitor in metastatic melanoma.
Sokołowska-Wojdyło M; Olszewska B; Sobjanek M; Sławińska M; Sosińska-Mielcarek K; Biernat W; Nowicki R
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e83-e84. PubMed ID: 28857272
[No Abstract] [Full Text] [Related]
30. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Ribas A; Algazi A; Ascierto PA; Butler MO; Chandra S; Gordon M; Hernandez-Aya L; Lawrence D; Lutzky J; Miller WH; Campbell KM; Delafont B; Marshall S; Mueller N; Robert C
Nat Commun; 2020 Dec; 11(1):6262. PubMed ID: 33288749
[TBL] [Abstract][Full Text] [Related]
31. Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib.
Rueda-Rueda T; Sánchez-Vicente JL; Moruno-Rodríguez A; Molina-Socola FE; Martínez-Borrego AC; López-Herrero F
Arch Soc Esp Oftalmol (Engl Ed); 2018 Sep; 93(9):458-462. PubMed ID: 29580759
[TBL] [Abstract][Full Text] [Related]
32. Bilateral Ischemic Retinal Vasculitis in Metastatic Cutaneous Melanoma Patient Treated with Dabrafenib and Trametinib: A Case Report.
Niro A; Recchimurzo N; Sborgia A; Guida M; Alessio G
Ocul Immunol Inflamm; 2018; 26(5):783-785. PubMed ID: 27973971
[No Abstract] [Full Text] [Related]
33. MAP-kinase pathway up or down? Just look at the skin of your patients!
Robert C; Thomas M; Mateus C
Melanoma Res; 2014 Oct; 24(5):421-3. PubMed ID: 25185691
[No Abstract] [Full Text] [Related]
34. Pyrexia by COVID-19 in a patient treated with dabrafenib/trametinib therapy.
Hashimoto H; Ito T; Ide T; Sasaki N; Hikichi S; Furue M
J Dermatol; 2021 Feb; 48(2):e122-e123. PubMed ID: 33200424
[No Abstract] [Full Text] [Related]
35. Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib.
Winkler JK; Buder-Bakhaya K; Ellert E; Herpel E; Martens UM; Enk A; Hassel JC
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e31-e32. PubMed ID: 28695986
[No Abstract] [Full Text] [Related]
36. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte colony-stimulating factor-producing melanoma treated with the combination of dabrafenib and trametinib.
Minowa T; Kato J; Hida T; Horimoto K; Sato S; Sawada M; Takahashi H; Uhara H
Int J Dermatol; 2018 Jul; 57(7):e31-e33. PubMed ID: 29655274
[No Abstract] [Full Text] [Related]
38. Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.
Muto Y; Ng W; Namikawa K; Takahashi A; Tsutsumida A; Nishida M; Yamazaki N
Melanoma Res; 2018 Apr; 28(2):151-154. PubMed ID: 29356791
[TBL] [Abstract][Full Text] [Related]
39. Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.
Martín Algarra S; Soriano V; Fernández-Morales L; Berciano-Guerrero MÁ; Mujika K; Manzano JL; Puértolas Hernández T; Soria A; Rodríguez-Abreu D; Espinosa Arranz E; Medina Martínez J; Márquez-Rodas I; Rubió-Casadevall J; Ortega ME; Jurado García JM; Lecumberri Biurrun MJ; Palacio I; Rodríguez de la Borbolla Artacho M; Altozano JP; Castellón Rubio VE; García A; Luna P; Ballesteros A; Fernández O; López Martín JA; Berrocal A; Arance A
Medicine (Baltimore); 2017 Dec; 96(52):e9523. PubMed ID: 29384960
[TBL] [Abstract][Full Text] [Related]
40. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
Irimada M; Fujimura T; Kambayashi Y; Tsukada A; Takahashi T; Hashimoto A; Aiba S
J Dermatol; 2019 Jul; 46(7):e256-e258. PubMed ID: 30656733
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
